The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Open accessAbstract
Histone deacetylases (HDACs) are enzymes that catalyze the removal of acetyl functional groups from the lysine residues of both histone and nonhistone proteins. In humans, there are 18 HDAC enzymes that use either zinc- or NAD(+)-dependent mechanisms to deacetylate acetyl lysine substrates. Although removal of histone acetyl epigenetic modification by HDACs regulates chromatin structure and transcription, deacetylation of nonhistones controls diverse cellular processes. HDAC inhibitors are already known potential anticancer agents and show promise for the treatment of many diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK
Lin, Y.-Y., Kiihl, S. F., Suhail, Y., Liu, S., Chou, Y., Kuang, Z., Lu, J., Khor, C. N., Lin, C.-L., Bader, J. S., et al. (2012) · Nature · doi:10.1038/nature10804 · Cited by 108
RetractedLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS
Allfrey, V. G., Faulkner, R., & Mirsky, A. E. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.51.5.786 · Cited by 2,639
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 2×
“Indeed, the different sensitivity of HDAC6 to TSA and trapoxin was used for identifying atubulin as an important HDAC6 substrate (Hubbert et al. 2002; Matsuyama et al. 2002).”
BackgroundSelf-citation
Cited by
The molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Self-citationFrangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Histone Modifications and Cancer
Audia, J. E., & Campbell, R. M. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019521 · Cited by 1,024
Heavy metals: toxicity and human health effects
Jomova, K., Alomar, S. Y., Nepovimova, E., Kuca, K., & Valko, M. (2025) · Archives of Toxicology · doi:10.1007/s00204-024-03903-2 · Cited by 983
Modulation of cellular processes by histone and non-histone protein acetylation
Shvedunova, M., & Akhtar, A. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00441-y · Cited by 936
Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
Moreno-Yruela, C., Zhang, D., Wei, W., Bæk, M., Liu, W., Gao, J., Danková, D., Nielsen, A. L., Bolding, J. E., Yang, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi6696 · Cited by 841
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 754
Writers and Readers of Histone Acetylation: Structure, Mechanism, and Inhibition
Marmorstein, R., & Zhou, M.-M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018762 · Cited by 638
A short guide to histone deacetylases including recent progress on class II enzymes
Park, S.-Y., & Kim, J.-S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0382-4 · Cited by 509
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
Wu, Y.-L., Lin, Z.-J., Li, C.-C., Lin, X., Shan, S.-K., Guo, B., Zheng, M.-H., Li, F., Yuan, L.-Q., & Li, Z.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01333-7 · Cited by 476
Overview of Histone Modification
Zhang, Y., Sun, Z., Jia, J., Du, T., Zhang, N., Tang, Y., Fang, Y., & Fang, D. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-8104-5_1 · Cited by 467
Zhu, S., Chen, W., Masson, A., & Li, Y.-P. (2024) · Cell Discovery · doi:10.1038/s41421-024-00689-6 · Cited by 463
Epigenetic Regulation in Plants
Pikaard, C. S., & Mittelsten Scheid, O. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019315 · Cited by 440
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism
Cui, Z., Zhao, X., Amevor, F. K., Du, X., Wang, Y., Li, D., Shu, G., Tian, Y., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943321 · Cited by 377
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Mitochondria and Epigenetics – Crosstalk in Homeostasis and Stress
Matilainen, O., Quirós, P. M., & Auwerx, J. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.02.004 · Cited by 364
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
Sanchez, H. N., Moroney, J. B., Gan, H., Shen, T., Im, J. L., Li, T., Taylor, J. R., Zan, H., & Casali, P. (2020) · Nature Communications · doi:10.1038/s41467-019-13603-6 · Cited by 361
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Post-translational regulation of ubiquitin signaling
Song, L., & Luo, Z.-Q. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201902074 · Cited by 346
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
The Role of Epigenetics in Autoimmune/Inflammatory Disease
Surace, A. E. A., & Hedrich, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01525 · Cited by 302
The role of histone modifications: from neurodevelopment to neurodiseases
Park, J., Lee, K., Kim, K., & Yi, S.-J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01078-9 · Cited by 297
Tatone, C., Di Emidio, G., Barbonetti, A., Carta, G., Luciano, A. M., Falone, S., & Amicarelli, F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy003 · Cited by 294
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 287
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284
Transcriptional and Epigenomic Regulation of Adipogenesis
Lee, J.-E., Schmidt, H., Lai, B., & Ge, K. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-18 · Cited by 267
Transcriptional Silencing by Polycomb-Group Proteins
Grossniklaus, U., & Paro, R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019331 · Cited by 263
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies
Mueller, A.-L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021) · Cells · doi:10.3390/cells10113017 · Cited by 256
HDAC6 as privileged target in drug discovery: A perspective
Pulya, S., Amin, S. A., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105274 · Cited by 253
Metabolic regulation of chromatin modifications and gene expression
Schvartzman, J. M., Thompson, C. B., & Finley, L. W. S. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201803061 · Cited by 233
Pao, P.-C., Patnaik, D., Watson, L. A., Gao, F., Pan, L., Wang, J., Adaikkan, C., Penney, J., Cam, H. P., Huang, W.-C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16361-y · Cited by 216
Kumar, V., Kundu, S., Singh, A., & Singh, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666210609160017 · Cited by 210
Integrative regulation of physiology by histone deacetylase 3
Emmett, M. J., & Lazar, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0076-0 · Cited by 202
HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2
Cao, J., Sun, L., Aramsangtienchai, P., Spiegelman, N. A., Zhang, X., Huang, W., Seto, E., & Lin, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815365116 · Cited by 189
Self-citationMolecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Terranova-Barberio, M., Thomas, S., Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M. D., Budillon, A., & Munster, P. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23169 · Cited by 182
Histone deacetylase 11 is a fatty-acid deacylase
Kutil, Z., Novakova, Z., Meleshin, M., Mikesova, J., Schutkowski, M., & Barinka, C. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00942 · Cited by 174
Witt, A. E., Lee, C.-W., Lee, T. I., Azzam, D. J., Wang, B., Caslini, C., Petrocca, F., Grosso, J., Jones, M., Cohick, E. B., et al. (2017) · Oncogene · doi:10.1038/onc.2016.337 · Cited by 172
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
Developing potent PROTACs tools for selective degradation of HDAC6 protein
An, Z., Lv, W., Su, S., Wu, W., & Rao, Y. (2019) · Protein & Cell · doi:10.1007/s13238-018-0602-z · Cited by 133
Programming and regulation of metabolic homeostasis by HDAC11
Sun, L., Marin de Evsikova, C., Bian, K., Achille, A., Telles, E., Pei, H., & Seto, E. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.06.025 · Cited by 125
Self-citationMarek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 122
Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121
Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019) · Oncogene · doi:10.1038/s41388-019-0897-0 · Cited by 121
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
Smalley, J. P., Adams, G. E., Millard, C. J., Song, Y., Norris, J. K. S., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2020) · Chemical Communications · doi:10.1039/d0cc01485k · Cited by 121
Targeted protein acetylation in cells using heterobifunctional molecules
Wang, W. W., Chen, L.-Y., Wozniak, J. M., Jadhav, A. M., Anderson, H., Malone, T. E., & Parker, C. G. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07850 · Cited by 114
Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0117 · Cited by 111
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
Plasticity in designing PROTACs for selective and potent degradation of HDAC6
Yang, H., Lv, W., He, M., Deng, H., Li, H., Wu, W., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c9cc08509b · Cited by 108
Gabriele, M., Lopez Tobon, A., D'Agostino, G., & Testa, G. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.013 · Cited by 103
HDAC inhibitors: A new promising drug class in anti-aging research
Pasyukova, E. G., & Vaiserman, A. M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.008 · Cited by 99
Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function
Huang, J., Wang, L., Dahiya, S., Beier, U. H., Han, R., Samanta, A., Bergman, J., Sotomayor, E. M., Seto, E., Kozikowski, A. P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09211-3 · Cited by 96
Self-citationGarcia Morato, J., Hans, F., von Zweydorf, F., Feederle, R., Elsässer, S. J., Skodras, A. A., Gloeckner, C. J., Buratti, E., Neumann, M., & Kahle, P. J. (2022) · Nature Communications · doi:10.1038/s41467-022-28822-7 · Cited by 94
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138560 · Cited by 84
Bahl, S., & Seto, E. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03599-4 · Cited by 82
Self-citationTGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression
Jones, D. L., Haak, A. J., Caporarello, N., Choi, K. M., Ye, Z., Yan, H., Varelas, X., Ordog, T., Ligresti, G., & Tschumperlin, D. J. (2019) · Journal of Cell Science · doi:10.1242/jcs.233486 · Cited by 77
The role of altered protein acetylation in neurodegenerative disease
Kabir, F., Atkinson, R., Cook, A. L., Phipps, A. J., & King, A. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1025473 · Cited by 75
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73
Self-citationKlomp, M. J., Dalm, S. U., de Jong, M., Feelders, R. A., Hofland, J., & Hofland, L. J. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09607-z · Cited by 69
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms
Yue, L., Sharma, V., Horvat, N. P., Akuffo, A. A., Beatty, M. S., Murdun, C., Colin, C., Billington, J. M. R., Goodheart, W. E., Sahakian, E., et al. (2020) · Blood · doi:10.1182/blood.2019895326 · Cited by 67
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, F., Zwinderman, M., & Dekker, F. (2018) · Molecules · doi:10.3390/molecules23030551 · Cited by 66
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58
Yang, Y., Yang, C., Li, T., Yu, S., Gan, T., Hu, J., Cui, J., & Zheng, X. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2149 · Cited by 57
Decoding the Rosetta stone of mitonuclear communication
English, J., Son, J. M., Cardamone, M. D., Lee, C., & Perissi, V. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105161 · Cited by 55
HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3
Zang, W.-J., Hu, Y.-L., Qian, C.-Y., Feng, Y., Liu, J.-Z., Yang, J.-L., Huang, H., Zhu, Y.-Z., & Xue, W.-J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01805-7 · Cited by 52
Azizi, P., Hanafi, M. M., Sahebi, M., Harikrishna, J. A., Taheri, S., Yassoralipour, A., & Nasehi, A. (2020) · Functional Plant Biology · doi:10.1071/fp19077 · Cited by 46
Poziello, A., Nebbioso, A., Stunnenberg, H. G., Martens, J. H. A., Carafa, V., & Altucci, L. (2021) · Epigenetics · doi:10.1080/15592294.2020.1827723 · Cited by 44
The role of protein acetylation in carcinogenesis and targeted drug discovery
Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42
Liu, T., Wang, X., Hu, W., Fang, Z., Jin, Y., Fang, X., & Miao, Q. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.011 · Cited by 41
A distal regulatory region of a class I human histone deacetylase
Werbeck, N. D., Shukla, V. K., Kunze, M. B. A., Yalinca, H., Pritchard, R. B., Siemons, L., Mondal, S., Greenwood, S. O. R., Kirkpatrick, J., Marson, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17610-w · Cited by 40
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
Diener, J., Baggiolini, A., Pernebrink, M., Dalcher, D., Lerra, L., Cheng, P. F., Varum, S., Häusel, J., Stierli, S., Treier, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25326-8 · Cited by 34
Histone Deacetylases 1 and 2 in Memory Function
Pao, P.-C., & Tsai, L.-H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00775 · Cited by 34
Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells
Lo Cascio, C., McNamara, J. B., Melendez, E. L., Lewis, E. M., Dufault, M. E., Sanai, N., Plaisier, C. L., & Mehta, S. (2021) · JCI Insight · doi:10.1172/jci.insight.149232 · Cited by 33
Measuring histone deacetylase inhibition in the brain
Reddy, D. S., Wu, X., Golub, V. M., Dashwood, W. M., & Dashwood, R. H. (2018) · Current Protocols in Pharmacology · doi:10.1002/cpph.41 · Cited by 33
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
Mani, C., Tripathi, K., Luan, S., Clark, D. W., Andrews, J. F., Vindigni, A., Thomas, G., & Palle, K. (2020) · Oncogene · doi:10.1038/s41388-020-1167-x · Cited by 27
HDAC8 functions in spindle assembly during mouse oocyte meiosis
Zhang, K., Lu, Y., Jiang, C., Liu, W., Shu, J., Chen, X., Shi, Y., Wang, E., Wang, L., Hu, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15383 · Cited by 27
Nakagawa, T., Hattori, S., Nobuta, R., Kimura, R., Nakagawa, M., Matsumoto, M., Nagasawa, Y., Funayama, R., Miyakawa, T., Inada, T., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101030 · Cited by 27
Targeting interleukin-17 as a novel treatment option for fibrotic diseases
Sisto, M., & Lisi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010164 · Cited by 22
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Ismail, N. H., Mussa, A., Zakaria, N. A., Al-Khreisat, M. J., Zahidin, M. A., Ramli, N. N., Mohammad, S. N. N. A., Hassan, R., Mohd Noor, N. H., Iberahim, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112767 · Cited by 22
Functional investigations of p53 acetylation enabled by heterobifunctional molecules
Chen, L.-Y., Singha Roy, S. J., Jadhav, A. M., Wang, W. W., Chen, P.-H., Bishop, T., Erb, M. A., & Parker, C. G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00438 · Cited by 18
IPMK regulates HDAC3 activity and histone H4 acetylation in human cells
Sowd, G. A., Stivison, E. A., Chapagain, P., Hale, A. T., Poland, J. C., Rameh, L. E., & Blind, R. D. (2024) · doi:10.1101/2024.04.29.591660 · Cited by 6
HDAC inhibitors support long-term expansion of porcine hepatocytes in vitro
Li, G., Zeng, M., Yan, Z., Cai, S., Ma, Y., Wang, Y., Li, S., Li, Y., Zhong, K., Xiao, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116973 · Cited by 2
A small molecule PTER-selective inhibitor reduces food intake and body weight
Fu, S., Wang, L., Li, V. L., Lyu, X., Wei, W., Shi, X., Deng, S., Barber, J. L., Tahir, U. A., Adams, C., et al. (2026) · Cell Chemical Biology · doi:10.1016/j.chembiol.2026.02.005 · Cited by 2
A small molecule PTER-selective inhibitor reduces food intake and body weight
Fu, S., Wang, L., Li, V. L., Lyu, X., Wei, W., Shi, X., Deng, S., Barber, J. L., Tahir, U. A., Adams, C., et al. (2026) · doi:10.64898/2026.01.26.701829 · Cited by 2
Non-hydrolyzable acetyllysine analogs to study protein acetylation in vitro and in cells
Kienle, S. M., Sigg, M., Schneider, T., Stuber, K., Lehmann, J., Jansen, J., Stengel, F., Marx, A., Kovermann, M., & Scheffner, M. (2026) · Nature Communications · doi:10.1038/s41467-026-69782-6
Metadata
- Authors
- Seto, E., & Yoshida, M.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-04-01
- Volume
- 6
- Issue
- 4
- Pages
- a018713-a018713
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2113056756
- Cited by
- 1,989
- References
- 122
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.